Cost Analysis of Human Islet Transplantation for the Treatment of Type 1 Diabetes in the Swiss-French Consortium GRAGIL

Diabetes Care

Volumn 27, Issue 4, 2004, Pages 895-900

  Guignard, Adrienne P ^a   Oberholzer, José ^b   Benhamou, Pierre Yves ^c   Touzet, Sandrine ^a   Bucher, Pascal ^b   Penfornis, Alfred ^d   Bayle, François ^c   Kessler, Laurence ^e   Thivolet, Charles ^f   Badet, Lionel ^a   Morel, Philippe ^b   Colin, Cyril ^a  

^a Hospices Civils ^*  (France)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIDIABETIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CELL ISOLATION; COST BENEFIT ANALYSIS; DRUG COST; ECONOMIC ASPECT; FOLLOW UP; FRANCE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; PANCREAS ISLET TRANSPLANTATION; SCREENING; SWITZERLAND;

CHEMOTHERAPY, ADJUVANT; COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 1; FRANCE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSION; ISLETS OF LANGERHANS TRANSPLANTATION; KIDNEY TRANSPLANTATION; SWITZERLAND; TISSUE AND ORGAN HARVESTING; TISSUE AND ORGAN PROCUREMENT;

EID: 12144285751     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.4.895     Document Type: Article

References (28)

1. Boker A, Rothenberg L, Hernandez C, Kenyon NS, Ricordi C, Alejandro R: Human islet transplantation: update. World J Surg 25:481-486, 2001
2. Robertson RP: Pancreatic islet cell transplantation: likely impact on current therapeutics for type 1 diabetes mellitus. Drugs 61:2017-2020, 2001
3. Serup P, Madsen QD, Mandrup-Poulsen T: Islet and stem cell transplantation for treating diabetes. BMJ 322:29-32, 2001
4. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
5. Diabetes Control and Complications Trial Research Group: Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 276:1409-1415, 1996
6. Palmer AJ, Weiss C, Sendi PP, Neeser K, Brandt A, Singh G, Wenzel H, Spinas GA: The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective. Diabetologia 43:13-26, 2000
7. Laditka SB, Mastanduno MP, Laditka JN: Health care use of individuals with diabetes in an employer-based insurance population. Arch Intern Med 161:1301-1308, 2001
8. Currie CJ, Morgan CJ, Peters JR: The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy, and ulceration in diabetes. Diabetes Care 21:42-48, 1998
9. American Diabetes Association: Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 21: 296-309, 1998
10. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Wagner EH: Patient-level estimates of the cost of complications in diabetes in a managed-care population. Pharmacoeconomics 16:285-295, 1999
11. Bjork S: The cost of diabetes and diabetes care. Diabetes Res Clin Pract 54 (Suppl. 1):S13-S18, 2001
12. Klonoff DC, Schwartz DM: An economic analysis of interventions for diabetes. Diabetes Care 23:390-404, 2000
13. Stevens RB, Matsumoto S, Marsh CL: Is islet transplantation a realistic therapy for the treatment of type 1 diabetes in the near future? Clinical Diabetes 19:51-60, 2001
14. Brendel MD, Hering BJ, Schultz AO, Bretzel RG: International Islet Transplant Registry: Newsletter 9. Giessen, Germany, University Hospital Giessen, 2001
15. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid free immunosuppressive regimen. N Engl J Med 343:230-237, 2000
16. Ryan EA, Lakey JR, Rajotte RV, Korbutt GS, Kin T, Imes S, Rabinovitch A, Elliott JF, Bigam D, Kneteman NM, Warnock GL, Larsen I, Shapiro AM: Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 50:710-719, 2001
17. 2000 Annual Report of the U.S. Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant Data: 1990-1999. Rockville, MD, U.S. Department of Health and Human Services, Health Resources and Services Administration, Office of Special Programs, Division of Transplantation, Richmond, VA, United Network for Organ Sharing, 2000
18. Manske CL: Risks and benefits of kidney and pancreas transplantation for diabetic patients. Diabetes Care 22 (Suppl. 2): B114-13120, 1999
19. Federlin K, Pozza G: Indications for clinical islet transplantation today and in the foreseeable future: the diabetologist's point of view. J Mol Med 77:148-152, 1999
20. Benhamou PY, Oberholzer J, Toso C, Kessler L, Penfornis A, Bayle F, Thivolet C, Martin X, Ris F, Badet L, Colin C, Morel P: Human islet transplantation network for the treatment of type I diabetes: first data from the Swiss-French GRAGIL consortium (1999-2000). Diabetologia 44: 859-864, 2001
21. Oberholzer J, Triponez F, Mage R, Andereggen E, Buhler L, Cretin N, Fournier B, Goumaz C, Lou J, Philippe J, Morel P: Human islet transplantation: lessons from 13 autologuous and 13 allogeneic transplantations. Transplantation 69:1115-1123, 2000
22. Oberholzer J, Toso C, Ris F, Bucher P, Triponez F, Demirag A, Lou J, Morel P: Beta cell replacement for the treatment of diabetes. Ann N Y Acad Sci 944:373-387, 2001
23. Toso C, Oberholzer J, Ris F, Triponez F, Bucher P, Demirag A, Andereggen E, Buehler L, Cretin N, Fournier B, Majno P, Hong Y, Lou J, Morel P: Factors affecting human islet of Langerhans isolation yields. Transplant Proc 34:826-827, 2002
24. Lenisa L, Castoldi R, Socci C, Motta F, Ferrari G, Pozza G, Di Carlo V: Cost analysis of kidney-pancreas and kidney-islet transplant. Transplant Proc 27:3061-3084, 1995
25. Echelle Nationale des Coûts relatifs par GHM, année 2000. Available from: http://www.le-pmsi.fr/telechargeables/mco/index.html. Accessed 15 August 2001
26. Ricordeau P, Weill A, Vallier N, Bourrel R, Fender P, Allemand H: The cost of diabetes in metropolitan France. Diabetes Metab 26 (Suppl. 6):25-38, 2000
27. Wagner EH, Sandhu N, Newton KM, Mc Culloch DK, Ramsey SD, Grothaus LC: Effect of improved glycemic control on health care costs and utilization. JAMA 285:182-189, 2001
28. Menzin J, Langley-Hawthorne C, Friedman M, Boulanger L, Cavanaugh R: Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care 24:51-55, 2001